Drugs / Pantogar
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT03659201 | Sep 2018 → Jun 2019 | telogen effluvium | EMS | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04880889 Comparator | Jan → Jul 2023 | telogen effluvium | Biolab Sanus Farmaceutica | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pantogar | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04880889 ↗ |
| Route | Oral | “Oral, placebo for 12 weeks and pantogar for 12 weeks.” NCT03659201 ↗ |